CD274 and non-small cell lung carcinoma: In addition, an ongoing phase I/IIa open-label, dose-escalation and expansion study (NCT04931654) is assessing the efficacy of the TIM-3/PD-1 bispecific antibody AZD7789 in NSCLC patients with acquired resistance to αPD-1/PD-L1 therapy.